The 58-year-old affected person with a historical past of bronchial asthma examined optimistic for the virus in September. He had a fever and issue respiration, however recovered in a number of days and examined unfavorable twice the next month, scientists wrote in a paper not too long ago revealed in Clinical Infectious Diseases.
More than 100 days later, he developed signs and examined optimistic but once more. Sequencing revealed a number of mutations attribute of the B.1.351 variant, altering the floor spike proteins. Per week later, the person’s situation worsened and he required air flow.
Scientists mentioned the pressure behind the primary optimistic take a look at wasn’t accessible for sequencing, although they famous the case occurred earlier than the pressure emerged in South Africa and months earlier than it was detected in France.
“This is, to our information, the primary description of reinfection with the South African SARS-CoV-2 VOC 501Y.V2 inflicting extreme COVID-19, 4 months after a primary delicate an infection,” examine authors wrote.
The pressure has sparked important concern as a result of it has elevated transmissibility and confirmed to diminish vaccines’ efficacy, with a number of corporations now planning for variant booster pictures to lift safety towards the strains.
The crew of French researchers mentioned “reinfections have been described however stay uncommon albeit most likely underestimated,” and resulting from undersurveillance, it’s troublesome to verify whether or not the researchers discovered the primary true case of reinfection with the variant, per the Washington Post.
This pressure has unfold worldwide since late final yr, and there are 17 reported circumstances throughout eight U.S. states, in accordance with the Centers for Disease Control and Prevention (CDC). Study authors say it’s nonetheless “controversial” whether or not prior an infection can defend towards reinfections.
“Our case illustrates that the 501Y.V2 SARS-CoV-2 variant can be accountable for extreme reinfections after a primary delicate an infection with non-VOC SARS-CoV-2,” reads the examine. “Further investigation is urgently wanted to evaluate cross immunity towards VOC 501Y.V2, and to observe vaccine effectiveness towards new variants.”